A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy  by Pollicita, M. et al.
RESEARCH NOTE VIROLOGYA recent epidemiological cluster of acute
hepatitis B genotype F1b infection in a
restricted geographical area of ItalyM. Pollicita1, C. Alteri1, M. C. Bellocchi1, D. Armenia1,
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Hospital, Infectious Disease Unit, Avezzano and 4) ‘Spirito Santo’ Hospital,
Infectious Disease Unit, Pescara, ItalyAbstractIn this study, by phylogenetic analysis, we identiﬁed an
epidemiological cluster involving eight individuals diagnosed with
acute hepatitis B virus (HBV) infection related to unprotected
sexual intercourse in a restricted area of central Italy (time
period: 2011–2014). Notably, these patients (six of eight Italians)
were infected by subgenotype F1b, which is not commonly found
in western countries. Ultra-deep pyrosequencing conﬁrmed a
superimposable composition of HBV quasi-species in these
patients. Despite the availability of effective vaccination, this study
highlights the importance of not underestimating the risk of HBV
infection, of continuing to set up surveillance programmes for
HBV infection, and of investigating the pathogenetic potential of
these atypical genotypes.
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p://dx.doi.org/10.1016/j.cmi.2015.07.022BackgroundTen hepatitis B virus (HBV) genotypes (A–H plus tentative
genotypes I and J) and subgenotypes have been identiﬁed so far,
based on intergroup divergences of 8% and 4%, respectively, in
the complete HBV genome [1]. Among them, genotype F is
divided into four subgenotypes (F1–F4). Subgenotype F1 is
found in Central America (F1a), Alaska, and South America
(F1b), subgenotype F3 is found in Central America and in
northern South America, and subgenotypes F2a, F2b and F4 are
found in South America [2].
In this study, we describe a local epidemiological cluster of
acute HBV infection, sexually transmitted in a short time period,
involving eight individuals infected with subgenotype F1b.Materials and methodsThe protocols used for population and ultra-deep HBV
sequencing, and for phylogenetic analysis, are extensively
described in Doc. S1, Doc. S2, and Doc. S3.ResultsBetween November 2011 and May 2014, eight individuals (seven
females and one male) were diagnosed with acute HBV infection
in two hospitals of the Abruzzo region in central Italy (deﬁned as
A–H in Fig. 1 and Table 1). The deﬁnition of acute HBV infection
was based on: hepatitis B surface antigen (HBsAg) and IgM anti-
hepatitis B core antibody positivity, and alanine transaminase
levels 10 times the normal value. All patients had a clinical
history compatible with acute HBV infection.
All individuals reported having unprotected sexual inter-
course within weeks before the appearance of symptoms.
Speciﬁc risk factors for blood-related transmission were
excluded (no tattoos, no transfusion of blood or blood de-
rivatives, no drug use, and no unsafe healthcare-related injec-
tion practices). No patients worked in a healthcare setting or
lived with HBsAg-positive individuals.
Six individuals (not vaccinated for HBV) were Italian (age
range, 37–59 years), and two were from the Philippines and
Argentina (aged 26 years and 44 years, respectively) (Table 1).
HBV infection spontaneously resolved in the seven women
(patients B–H) (HBsAg negative, anti-hepatitis B core antibody
positive ± anti-hepatitis B surface antibody positive). In the only
man (patient A) showing HBsAg persistence for 6 months, the
infection resolved as a consequence of anti-HBV treatment.ious Diseases. Published by Elsevier Ltd. All rights reserved
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TABLE 1. Characteristics of patients
Characteristics
Patients
A B C D E F G H
Sex Male Female Female Female Female Female Female Female
Nationality Italian Italian Phillipine Italian Italian Italian Italian Argentinian
Age (years) 59 37 26 40 43 58 39 44
Date of blood sample collectiona March 2012 February 2014 February 2014 November 2013 November 2013 September 2013 September 2013 May 2014
Serum HBV DNA (IU/mL)b >170 000 000 462 6490 5233 54 346 176 1578 44 346
ASTb 55 341 1510 1776 565 1379 61 1421
ALTb 157 1305 2227 2663 2324 2237 122 1865
HBsAg (IU/mL)b 115 261 7765 10 292 153 1360 23 1481 Positivec
Anti-HBsb – – – – – – – –
HBeAgb + + + + – + – NA
Anti-HBe – + – + + – + NA
HBcAg IgG/IgMb + + + + + + + +
ALT, alanine transaminase; AST, aspartate transaminase; HBcAg, hepatitis B core antigen; HBe, hepatitis B e antibody; HBeAg, hepatitis B e antigen; HBs, hepatitis B surface antibody;
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not available.
aThis date refers to blood sample withdrawal for genotypic testing.
bValues are those observed at the time of genotypic testing.
cFor this patient, only qualitative HBsAg data were available.
1124.e3 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIFor diagnostic purposes, a genotypic test based on the
population-based sequencing of HBV reverse transcriptase
(RT)/HBsAg (Doc. S1) was performed at the university hospital
‘Tor Vergata’, Rome, Italy. This test revealed no drug resistance
RT mutations, and some amino acids (wild type in subgenotype
F1b) at speciﬁc HBsAg positions (L110, T114, K122, L127,
F134, and S140) that are known to affect HBsAg recognition by
antibodies (http://hbv.bioinf.mpi-inf.mpg.de/index.php).
Phylogenetic analysis with the neighbour-joining method (Doc.
S2) showed that the RT sequences from the eight individuals
belonged to subgenotype F1b, and formed a well-deﬁned cluster
(bootstrap value of >90%) (Fig. S1). Once the HBV genotype had
been assigned, the statistical robustness of the cluster was
conﬁrmed by use of a maximum-likelihood tree (Doc. S2), con-
taining only F1b RT sequences and F1a RT sequences used as the
outgroup (Fig. 1a). Again, RT sequences from the eight individuals
formed a cluster distinct from the other 70 F1b RT sequences
included in the analysis (bootstrap value of >85%) (Fig. 1a).
This cluster was also conﬁrmed by analysing concatenated
F1b basic core promoter (BCP)/precore/core/RT sequences
(bootstrap value of >85%) (Fig. 1b).
Finally, the mean genetic distance in both RT and BCP/pre-
core/core sequences involved in the cluster was extremely low
(RT, 0.00006, standard error ±0.00001; BCP/precore/core,FIG. 1. (a) A maximum-likelihood phylogenetic tree was constructed by using
70 isolates downloaded from GenBank, eight individuals involved in the clust
university hospital ‘Tor Vergata’ (identiﬁed with arabic numbers). Two HBV F
phylogenetic tree was constructed by using concatenated HBV F1b basic
downloaded from GenBank, and ﬁve individuals involved in the cluster. Two
Branch lengths were estimated with the best-ﬁtting nucleotide substitution mo
bar at the bottom indicates 0.001 nucleotide substitutions per site. The asteris
involving the eight HBV F1b RT sequences and the ﬁve concatenated RT/HB
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect0.00001, standard error ±0.0000001), conﬁrming high homol-
ogy among sequences.
Furthermore, the composition of HBV quasi-species in the
eight individuals involved in the cluster was investigated by
ultra-deep pyrosequencing, performed on the RT/HBsAg and
BCP/precore/core regions (Doc. S3).
The patterns of mutations detected in these genomic regions,
with an intrapatient prevalence ranging from 10% to 100%, were
superimposable in all eight individuals (Supplementary data).
Only in patient H, additional mutations were detected in
BCP, all with a prevalence of 100% (Supplementary data).
Conversely, the patternsofmutationsdetected in theRT/HBsAg
and BCP/precore/core regions, with an intrapatient prevalence of
<10%, varied among the patients (Supplementary data), suggesting
genetic diversiﬁcation only at the level of minority species.DiscussionThis study provides molecular evidence of a local epidemio-
logical cluster involving eight individuals, diagnosed with acute
HBV infection related to unprotected sexual intercourse, in a
restricted area of central Italy (all resident in two cities no more
than 115 km apart) in a short period of time.hepatitis B virus (HBV) F1b reverse transcriptase (RT) sequences from:
er, and two individuals collected from routine laboratory testing at the
1a RT sequences were used as the outgroup. (b) A maximum-likelihood
core promoter (BCP)/precore/core/RT sequences from: 58 isolates
HBV F1a BCP/precore/core/RT sequences were used as the outgroup.
del (GTR + G + I) according to a hierarchical likelihood ratio test. The
ks (*) along a branch represent bootstrap support of >85%. The clusters
sAg/BCP/precore/core sequences are in the grey box.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1124.e1–1124.e4
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mainly in the setting of nosocomial infections [1,3]. To our
knowledge, this is the ﬁrst study showing an epidemiological
cluster not sustained by an iatrogenic route of infection.
We emphasize that this is an epidemiological cluster and not
a transmission chain. Thus, we cannot exclude the involvement
of other individuals (not identiﬁed) contributing to HBV/F1b
transmission.
In the cluster identiﬁed, the eight individuals were not
vaccinated: six Italians and two from countries where the
vaccination coverage is medium to low. In Italy, the nationwide
HBV vaccination programme has targeted all infants born since
1992, and adolescents born between 1980 and 1991. Thus,
there is a reservoir of the Italian population (sexually active)
born before 1980 that is susceptible to HBV infection. This
suggests the importance of encouraging a larger proportion of
adult individuals to be vaccinated for HBV, and of offering HBV
vaccination to foreign individuals who are negative for HBV
infection.
This epidemiological cluster was sustained by subgenotype
F1b, which is not commonly found in Europe. This raises the
issue of the circulation of non-D and non-A genotypes pro-
gressively increasing in western countries. Epidemiological
models have shown that, in the future, HBV epidemiology will
be substantially modiﬁed by waves of immigration, affecting the
local prevalence of HBV infection and routes of transmission,
and impacting on prophylactic, diagnostic and therapeutic
measures [4,5]. The imported HBV infections can be also
transmitted to the native population (as described in this clus-
ter), further contributing to the spread of atypical genotypes.
Furthermore, HBV genotypes are known to profoundly
affect the natural history of HBV infection. In particular, it is
known that genotypes C and E result in faster progression to
liver cancer [6]. This was also recently described for genotype F
[2]. Thus, the increased prevalence of these genotypes in
western countries may have implications for the burden and
clinical management of liver-related morbidity and mortality.
In the epidemiological cluster identiﬁed, acute HBV infection
resolved in all individuals. It is known that the resolution of acute
HBV infection does not imply HBV eradication, but its persis-
tence in an occult form in the vast majority of patients [7–9].
Occult HBV infection is recognized as a cofactor promoting liver
cancer [10,11], and can reactivate spontaneously or under
immunosuppressive conditions. These observations suggest that
interventions should be set up with the aim of promoting
screening and (when necessary) treatment for the migrant
groups coming from countries with a high HBV prevalence.
In conclusion, despite the availability of effective vaccination,
this study highlights the need to not underestimate the risk of HBV
infection, to continue to set up surveillance programmes for HBVClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeinfection, and to investigate the pathogenetic potential of these
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